Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II platform study of GHZ339 in moderate to severe atopic dermatitis
CTR20253287Phase 2Active
- Sponsor
- Novartis
- Start
- Oct 2025
- Countries
- 1
01
Overview
A Phase 2 trial of GHZ339 in atopic dermatitis (AD), sponsored by Novartis. Started Oct 2025; status: active.
02
Drugs
GHZ339
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20253287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253287.